Nintedanib is named as an intervention in 2 current clinical trials in our UK, USA and India registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1). The most-studied condition is Systemic Sclerosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
RCT of Nintedanib in Fibrotic Sarcoidosis
NCT06479603 · ClinicalTrials.gov ↗ · Sarcoidosis, Pulmonary
|
Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | India |
|
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562 · ClinicalTrials.gov ↗ · Systemic Sclerosis
|
Phase 3 | Not yet open | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 0 |
| Clinical trials in USA | 1 | 0 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA and India registers name Nintedanib as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) and Post Graduate Institute of Medical Education and Research, Chandigarh (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nintedanib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nintedanib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nintedanib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.